Systemic lupus erythematosus reduces survival of ICU patients mediated by renal dysfunction: retrospective study of critically ill patients.

Researchers studied whether systemic lupus erythematosus (SLE), an autoimmune disease that affects multiple organs, influences survival rates for patients in intensive care units. They analyzed data from over 50,000 critically ill patients in the United States between 2008 and 2019. The study found that ICU patients with SLE had significantly lower 180-day survival rates compared to those without the condition. Importantly, the researchers discovered that kidney dysfunction was the main reason SLE patients had worse outcomes—the disease's effect on the kidneys served as a key factor linking SLE to reduced survival. The study also revealed that SLE patients who were treated with glucocorticoid medications (steroids) did not show the same significant decrease in survival as those who weren't taking these drugs, suggesting that glucocorticoid treatment may help protect against some of the life-threatening effects of SLE in critically ill patients. For patients with SLE, this research highlights the critical importance of monitoring and protecting kidney function, especially during severe illness. While this study focused on conventional medical treatment in hospital settings, patients with SLE who are interested in complementary approaches like acupuncture should discuss their options with both their rheumatologist and integrative medicine team, as managing this complex condition requires careful coordination of care. Always seek treatment from a licensed acupuncturist with experience in autoimmune conditions.

This retrospective cohort study analyzed 50,920 critically ill patients from the MIMIC IV database (2008-2019) to assess survival outcomes in SLE patients requiring intensive care. Using matched controls to minimize confounders, researchers found SLE patients demonstrated significantly reduced 180-day survival (HR=1.485, P=0.015). Univariate Cox regression identified hemoglobin, platelets, white blood cells, creatinine, urine output, and SOFA scores as significant factors, but multivariate analysis isolated creatinine and urine output as independent predictors. Mediation analysis revealed renal dysfunction (measured by creatinine) as the primary mechanism by which SLE reduces survival in critically ill patients. Subgroup analysis showed glucocorticoid-treated SLE patients had non-significant survival reduction (HR=1.482, P=0.095) versus significant reduction in untreated patients (HR=1.660, P=0.027). Clinical takeaway: Renal function preservation is paramount in critically ill SLE patients, and glucocorticoid therapy may confer survival benefits through renal protective mechanisms.